Although our study might have included cases of poor preoperative visual acuities, with poor DM control and advanced retinopathy, we have evaluated the visual outcomes of anti-VEGF treatments in four reports [12-14,49] by adapting the baseline visual acuity range and measurement year of the visual acuity. This evidence concerns the gene VEGFA and retinal disorder.